Search results
Results from the WOW.Com Content Network
This will occur with most of the non-related donor. When transplanting HSC during AML, T-cells are usually selectively depleted to prevent GvHD while NK cells help with the GvL effect which prevent leukemia relapse. When using non-depleted T-cell transplant, cyclophosphamide is used after transplantation to prevent GvHD or transplant rejection.
Relapse rate has been recorded as high as 50%. If the first treatment was not entirely successful, many children have been brought into remission after a doctor recommended second stem cell transplant. [24] After bone marrow transplant, the relapse rate for children with JMML may be as high as 50%.
Graft-versus-host disease can largely be avoided by performing a T-cell-depleted bone marrow transplant. However, these types of transplants come at a cost of diminished graft-versus-tumor effect, greater risk of engraftment failure, or cancer relapse, [ 39 ] and general immunodeficiency , resulting in a patient more susceptible to viral ...
A recent study in mice suggests that bone marrow transplants from younger individuals may help fight Alzheimer's disease. The research has raised many questions. Young bone marrow transplants may ...
Further, immune suppressive medications are usually unnecessary if CD6+ T cells are removed from the donor marrow. [32] Patients can relapse even after a TCD allogeneic bone marrow transplant, though patients with chronic myelogenous leukemia (CML) who receive a donor lymphocyte infusion (DLI) can restore complete remission. [33]
The first physician to perform a successful human bone-marrow transplant on a disease other than cancer was Robert A. Good at the University of Minnesota in 1968. [75] In 1975, John Kersey, also of the University of Minnesota, performed the first successful bone-marrow transplant to cure lymphoma.
In keeping with the general behavior of chloromas, such an event must be regarded as an early herald of a systemic relapse, rather than as a localized process. In one review of 24 patients who developed isolated chloromas after treatment for acute myeloid leukemia, the mean interval until bone marrow relapse was 7 months (range, 1 to 19 months ...
Formerly, the only treatment option that offered relapsed bone marrow transplant patients hope of a cure was another bone marrow transplant. However, the risk of serious, life-threatening complications after a second BMT is great. One strategy of managing relapse, donor leukocyte infusion, might eliminate the need for a second BMT in some patients.